Categories: BrainNews

CervoMed to Participate in the Emerging Growth Conference

BOSTON, July 17, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will present virtually at the Emerging Growth Conference.

Presentation Details
Format: Corporate presentation
Date: Thursday, July 18, 2024
Time: 1:10 PM ET
Webcast Link: click here

The webcast of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579

Staff

Recent Posts

FendX Announces Grant of Stock Options and RSUs

Oakville, Ontario--(Newsfile Corp. - July 18, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

2 hours ago

Experience the Transformative Power of Tao Calligraphy Greatest Light at Arta Gallery

Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Arta Gallery is excited to announce the…

6 hours ago

ICF Selected for $88 Million Agreement to Support CMS Digital Modernization Work

Cloud Data Migration Will Optimize Healthcare Delivery and Patient Care RESTON, Va., July 18, 2024…

7 hours ago

Trella Health Unveils its 2024 Post-Acute Care Industry Trend Report

A comprehensive analysis of key trends, challenges, and opportunities driving the evolution of post-acute care.…

7 hours ago